In September 2024, Adar1 Capital analyst Mohit Gupta pitched an idea to Dan Schneeberger in Austin, Texas, to launch a new company focused on developing a long-acting antibody treatment for atopic dermatitis. This proposal represents a shift in strategy for Schneeberger, whose primary role at the biotech hedge fund is investing in existing drug-development companies rather than starting new ones from the ground up.
Adar1 Capital biotech company launch
- ▪In approximately September 2024, Adar1 Capital analyst Mohit Gupta pitched an idea to Dan Schneeberger at his Austin, Texas office to build a new biotech company from the ground up.
- ▪The biotech company proposed by Mohit Gupta to Adar1 Capital's Dan Schneeberger aims to develop a long-acting antibody treatment for atopic dermatitis.
Hedge fund drug development strategy
- ▪The proposal to build a new drug development company from the ground up represents a departure from Dan Schneeberger's typical investment practice at Adar1 Capital.
- ▪Dan Schneeberger's primary role at Adar1 Capital is to invest in existing biotechnology companies that are already actively developing drugs.
Story comments
Loading comments…